RxDoctor Payments Data

Rodanthee Goodell, APRN

Adult Health · Oklahoma City, OKNPI 1639110372

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,695 of the $2,283 with a category attached, or 74.2%. 13 manufacturers reported payments, led by Abbott at 52.7% of the total. Reporting peaked in 2023 at $1,299 and has fallen 92.6% since, to $96 in 2025.

$2,283in general payments, 2019–2025

Across 49 payments — averaging $46.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • E.r. Squibb & Sons, L.L.C.$291
  • Edwards Lifesciences$233
  • Boston Scientific$138
  • Irhythm Technologies, Inc.$105
  • Novartis$78
  • plus $236 from 7 others

What the payments were for

  • Travel & lodging$58826%
  • Food & beverage$1,69574%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,283 in reported general payments places this provider in the 75th percentile of 117 adult health providers in Oklahoma.

See all adult health providers in Oklahoma

Medicare billing

Part B allowed, 2024
$5,988
Medicare patients
67
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$93,199
EntrestoSacubitril/Valsartan56$65,619
FarxigaDapagliflozin Propanediol24$30,512
Repatha SureclickEvolocumab21$11,545
Metoprolol Succinate147$1,827
Atorvastatin Calcium107$1,743
Carvedilol55$945
ClopidogrelClopidogrel Bisulfate34$563
Lisinopril55$533
Nifedipine ErNifedipine21$529
Digoxin14$526
Ezetimibe25$447
Losartan Potassium32$388
Amlodipine Besylate61$365
Warfarin Sodium34$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$93,19982 claims
NovartisEntresto$78$65,61956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 adult health providers in Oklahoma.

Other adult health in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →